Key points are not available for this paper at this time.
Ruthenium aqua complexes (eta (6) -C (6) Me (6) ) Ru (II) (L) (OH (2) ) (2+) L = bpy (1) and 4, 4'-OMe-bpy (2), bpy = 2, 2'-bipyridine, 4, 4'-OMe-bpy = 4, 4'-dimethoxy-2, 2'-bipyridine and iridium aqua complexes Cp*Ir (III) (L) (OH (2) ) (2+) Cp* = eta (5) -C (5) Me (5), L = bpy (5) and 4, 4'-OMe-bpy (6) act as catalysts for hydrogenation of CO (2) into HCOOH at pH 3. 0 in H (2) O. The active hydride catalysts cannot be observed in the hydrogenation of CO (2) with the ruthenium complexes, whereas the active hydride catalysts, Cp*Ir (III) (L) (H) (+) L = bpy (7) and 4, 4'-OMe-bpy (8), have successfully been isolated after the hydrogenation of CO (2) with the iridium complexes. The key to the success of the isolation of the active hydride catalysts is the change in the rate-determining step in the catalytic hydrogenation of CO (2) from the formation of the active hydride catalysts, (eta (6) -C (6) Me (6) ) Ru (II) (L) (H) (+), to the reactions of Cp*Ir (III) (L) (H) (+) with CO (2), as indicated by the kinetic studies.
Ogo et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: